Scarica l'app Stockscreener
165.27
1.22%
2.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RGEN Giù?
Forum
Previsione
Repligen Corp Borsa (RGEN) Ultime notizie
Repligen Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Repligen Corp (RGEN) Q2 2026 Earnings Call Transcript - AlphaStreet
Is Repligen Corp (RGEN) Undervalued After Q2 Earnings Beat? EPS - GuruFocus
Repligen raises FY2026 adj EPS guidance to $2.03-$2.09 - scanx.trade
Repligen Reports Q2 2026: Revenue $204M, Adjusted EPS $0.54; Raises FY26 Guidance - TradingView
Repligen Reports Q2 2026 Revenue Growth, Raises Full-Year Organic Revenue and EPS Guidance - Quiver Quantitative
Repligen: Q2 Earnings Snapshot - Yahoo Finance
Repligen Corp (RGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Repligen Corp (RGEN) Institutional Confidence - TradingKey
RGEN|Repligen Corp|Price:131.960|Chg%:-5.640 - TradingKey
Repligen Corp (RGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Repligen (RGEN) Q2 Earnings: What To Expect - Yahoo! Finance Canada
Repligen Corp (RGEN) Cash Flow - TradingKey
ETFs Investing in Repligen Corporation Stocks - TradingView
Repligen Corp (RGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Repligen Corp (RGEN) Income Statement - TradingKey
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Repligen Corp (RGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RGEN|Repligen Corp|Price:130.800|Chg%:-1.160 - TradingKey
RGEN|Repligen Corp|Price:130.951|Chg%:-1.009 - TradingKey
Repligen’s $1.5 Billion Acquisition Could Reshape Its Growth Story! - Smartkarma
Repligen Corporation (RGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Daily Brief Health Care: Shanghai Shengsheng Pharmaceutical Cold Chain Technology, Akeso, Mitesco Inc, Nagaileben, Repligen Corp, Scribe Therapeutics, Cosmos Health and more - Smartkarma
Is Repligen Corp (RGEN) a Bargain After 4.1% Drop? GF Value Says Undervalued - GuruFocus
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know - Yahoo Finance
Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Repligen Corporation to Acquire BioLife Solutions for $1.5 Billion, Boosting Cell Therapy Market Presence - Kalkine Media
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-and-stock deal - Stock Titan
Repligen Corp (RGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout - Zacks Investment Research
Canaccord reiterates Hold on Repligen stock after BioLife deal By Investing.com - Investing.com India
RGEN stock holds steady as Repligen backs 2026 growth - Ad-hoc-news.de
Canaccord reiterates Hold on Repligen stock after BioLife deal - Investing.com
Bothell firm fetches $1.5 billion in acquisition by Massachusetts company - The Business Journals
Repligen to Acquire BioLife Solutions for $1.5 Billion, Expanding Leadership in Cell Therapy Market - Minichart
Repligen to Acquire Bothell's BioLife Solutions in $1.5B Deal - 425business.com
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-stock deal - Stock Titan
Repligen to Acquire BioLife Solutions for $11.25 per Share Plus Stock, Enhancing Cell Processing Capabilities - Kalkine Media
US759916AC3 Bond Profile — Key Metrics - TradingView
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach - Yahoo Finance
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business - ETPharma.com
Repligen targets cell therapy expansion as Waltham firm inks $1.5 billion acquisition - The Business Journals
Repligen to Acquire BioLife Solutions in $1.5 Billion Cash-and-Stock Deal, Expanding Into Cell Therapy - finance.biggo.com
Repligen beefs up cell therapy business with $1.5 billion deal for BioLife - Reuters
Repligen Announces Acquisition of BioLife Solutions in $11.25 Per Share Cash and Stock Deal - Kalkine Media
Repligen to Acquire BioLife Solutions in Cash and Stock Merger Valued at $11.25 Per Share - Kalkine Media
What's Going on With Repligen Stock Wednesday?Repligen (NASDAQ:RGEN), BioLife Solutions (NASDAQ:BLFS) - Benzinga
Repligen Corporation (Nasdaq: RGEN) sets cash–stock deal to buy BioLife - Stock Titan
Repligen to Acquire BioLife Solutions in Cash-and-Stock Deal; $11.25 Plus 0.1442 Shares Per Share - TradingView
Repligen Corp: If Deal Terminated Under Some - Moomoo
Repligen to Acquire BioLife Solutions in $1.5 Billion Deal - sekbernews.id
Repligen Corp To Acquire BioLife Solutions Transcript - GuruFocus
Repligen to buy cell therapy maker BioLife in $1.5 billion deal - MSN
Repligen to acquire BioLife Solutions for $1.5 billion - Investing.com
BioLife’s Biopreservation Media Supports 18 Commercially Approved Therapies - Stock Titan
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
A Look at Repligen Corp (RGEN) After 5.9% Decline -- GF Value $1 - GuruFocus
Why Repligen (RGEN) Stock Is Trading Lower Today - Yahoo Finance
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in cash and stock merger - Stock Titan
Form 4 Repligen Corporation For: 17 July By Investing.com - Investing.com South Africa
Repligen CFO Jason K Garland sells $79,500 in stock - Investing.com UK
Repligen CFO Jason K Garland sells $79,500 in stock By Investing.com - Investing.com Nigeria
Repligen CFO Jason Garland Sells 530 Shares Under Pre-Arranged Rule 10b5-1 Trading Plan - Kalkine Media
Insider Sell: Jason Garland Sells Shares of Repligen Corp (RGEN) - GuruFocus
0.40%
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):